XBiotech Inc
XBIT
Company Profile
Business description
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-IL-1 a therapeutic antibody as a treatment for cancer. Geographically, all of its operations are in the United States.
Contact
5217 Winnebago Lane
AustinTX78744
USAT: +1 512 386-2900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
92
Stocks News & Analysis
stocks
Investors overly negative on undervalued ASX share
Road to profitability is in sight as management continues to take the right steps.
stocks
Reporting season preview: February 2025
As of Wednesday, 24 companies under coverage have reported; you’ll find our analysis throughout this issue.
stocks
Signs of a turnaround for undervalued ASX share
Market likes the payoff from early efforts at reining in costs.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,811.90 | 13.20 | -0.15% |
CAC 40 | 8,184.41 | 5.87 | 0.07% |
DAX 40 | 22,705.62 | 192.20 | 0.85% |
Dow JONES (US) | 44,546.08 | 165.35 | -0.37% |
FTSE 100 | 8,752.61 | 20.15 | 0.23% |
HKSE | 22,616.23 | 4.10 | -0.02% |
NASDAQ | 20,026.77 | 81.13 | 0.41% |
Nikkei 225 | 39,174.25 | 24.82 | 0.06% |
NZX 50 Index | 13,068.93 | 79.75 | 0.61% |
S&P 500 | 6,114.63 | 0.44 | -0.01% |
S&P/ASX 200 | 8,537.10 | 18.70 | -0.22% |
SSE Composite Index | 3,355.83 | 9.11 | 0.27% |